Hello community. I am a researcher preparing a unique human dataset for Whole Genome Sequencing. The subject is a thirty-five year old male tracking to a nineteen year old biological baseline across multiple systems. This happens despite a high sugar diet and sedentary lifestyle.
We have verified anomaly biomarkers. The adaptive immunity index shows a ratio of five point nine. Cortical thymocytes are at zero point six percent which proves active thymogenesis. Endothelial inflammation is at absolute zero with ultra sensitive CRP less than zero point zero one. Insulin sensitivity index is zero point point fifty eight. Full lipid profile is optimal with cholesterol at one hundred thirty nine and triglycerides at forty three.
Which specific protective genetic variants or metabolic pathways like PCSK9 should we look for during target discovery once the WGS data is ready? Full panels for hematology and hepatic markers are available upon request.
•
written
by
evox.project •
1 answer
Thymus has a dual embryonic origin combining epithelial & lymphoid cells. Some pathways / factors to lookout for may be - Pro- & Anti-Inflammatory, TCRs, Cytokine signalling, Lipoproteins, Telomerase, Insulin / Cortisol / Somatostatin / Ghrelin / Leptin, Neuropeptide Y, ADH receptor, BMP, Carbohydrate Homeostasis, NAD+, Glutathione, Superoxide Dismutase, Homocysteine, NO, Adenosine, TNF-alpha, IL-6, Procalcitonin, Plasminogen, Heat Shock Proteins, Endogenous retroviruses, Cytochrome P450 etc. Metabolic Syndrome, Di George Syndrome, homeostatic, housekeeping, metabolic stress, telomeric, & immune variants could be significant.
Have you done a Literature Review? Family medical history? Trio WGS for De novo variants possible? Are you looking at receptor blockers, enzyme inhibitors, intercalators, antisense oligos, monoclonal ABs, miRNAs, KO / CRISPER strategies, binding-site variants, neoantigens etc.? Are you looking at SVs / CNVs / SNPs? Germline / Somatic targets or both? And what is the rationale for WGS as opposed to WXS / Clinical XS / Customised Targeted panel? GSEA / ORA / Variant Enrichment Analysis for downstream? Not sure i've added much to what you already know :-)
Log in to answer this question.
Additional context on metabolic resilience: Hepatic markers are pristine with ALT at thirteen point five and AST at nineteen point two. Renal clearance is exceptional with Cystatin C at zero point seventy nine and eGFR at one hundred seventeen. The key paradox is that this entire multi-system phenotype shield and absolute zero inflammation remain completely stable despite an excessive daily load of simple sugars, alcohol intake, and a lack of regular physical training. We are looking for pathways that actively buffer this metabolic stress.
Technical update (Cellular Hematology & Electrolyte Panels): Hemoglobin is 16 g/dL, Hematocrit is 45.7%, and Urea is 33.5 mg/dL. Iron panel shows Ferritin at 166.4 ng/mL and Serum Iron at 106 ug/dL. Leukocyte counts are White Blood Cells 4.66 10^3/mm^3, Red Blood Cells 4.85 10^6/mm^3, Thrombocytes 177 10^3/mm^3. Erythrocyte indices are MCV 94.2 fL, MCH 33 pg, MCHC 35 g/dL, and RDW 12.5%. Electrolyte balance is stable with Calcium 9.57 mg/dL, Phosphorus 3.64 mg/dL, Sodium 140 mmol/L, and Potassium 4.36 mmol/L.